Bevacizumab, the first vascular endothelial growth factor (VEGF) inhibitor approved for ovarian cancer, improved progression-free survival (PFS) when added to chemotherapy in newly diagnosed patients on ICON7 and GOG 0218, and recurrent disease on AURELIA (9–11). Here, VEGFA is linked to ovarian carcinoma.